Strikingly, combining IR700@Nb289‐OMVs (single dose) with CD47 nanobodies (two doses) achieved partial tumour eradication and durable immunological memory in subcutaneous and metastatic CRC models, outperforming PD‐1 blockade. This evidence concerns the gene CD47 and neoplasm.